Initial Phase 1/2 safety data for EN-374 in X-linked chronic granulomatous disease (X-CGD) demonstrate tolerability in first trial participant Updated preclinical data with Ensoma’s virus-like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results